Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises SCA in connection with the financing for the acquisition of BSN Medical from EQT
Mandate

Vinge advises SCA in connection with the financing for the acquisition of BSN Medical from EQT

December 21, 2016

BSN Medical develops, manufactures, markets and sells products within treatment of wounds, compression treatment and orthopaedics. The enterprise value amounts to EUR 2 740 000 000 (based on an estimated net debt as per 31 December 2016). The acquisition will be completely loan-financed and SCA has a binding credit assurance available. Clifford Chance in Germany represented SCA in relation to the acquisition and the banks were represented by Clifford Chance in London.

The transaction is conditional upon the salient regulatory approvals and is expected to be completed during the second quarter of 2017. The financial conditions governing the transaction have not been made public.
 
Vinge’s team consisted of Mikael Ståhl, Helena Håkansson and Lionardo Ojeda.

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025